McLeod phenotype without the McLeod syndrome

Transfusion

Volumn 47, Issue 2, 2007, Pages 299-305

  Walker, Ruth H ^a   Danek, Adrian ^b   Uttner, Ingo ^b   Offner, Robert ^b   Reid, Marion ^b   Lee, Soohee ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ADSORPTION; ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD EXAMINATION; BLOOD GROUP KELL SYSTEM; CASE REPORT; CLINICAL EXAMINATION; COGNITION; ELUTION; EVALUATION; GENE SEQUENCE; GENOTYPE; HUMAN; HYPERKINESIA; HYPERTRANSLUCENT LUNG; MALE; MISSENSE MUTATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PHENOTYPE; RADICULOPATHY; SEROLOGY;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; CHOREATIC DISORDERS; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; KELL BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; PHENOTYPE; SEVERITY OF ILLNESS INDEX; VARIATION (GENETICS);

EID: 33846418770     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01106.x     Document Type: Article

References (57)

1. Allen FH, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961;6:555-60.
2. Marsh WL, Marsh NJ, Moore A, et al. Elevated serum creatine phosphokinase in subjects with McLeod syndrome. Vox Sang 1981;40:403-11.
3. Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain 1983;106:717-33.
4. Witt TN, Danek A, Reiter M, et al. Mcleod syndrome: a distinct form of neuroacanthocytosis. Report of 2 cases and literature-review with emphasis on neuromuscular manifestations. J Neurol 1992;239:302-6.
5. Russo D, Redman C, Lee S. Association of XK and Kell blood group proteins. J Biol Chem 1998;273:13950-6.
6. Redman CM, Russo D, Lee S. Kell, Kx, and the McLeod syndrome. Baillieres Best Pract Res Clin Haematol 1999;12:621-35.
7. Ho MF, Chelly J, Carter N, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane-transport protein. Cell 1994;77:869-80.
8. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001;49:384-92.
9. Russo D, Wu X, Redman CM, et al. Expression of Kell blood group protein in nonerythroid tissues. Blood 2000;96:340-6.
10. Jung HH, Russo D, Redman C, et al. Kell and XK immunohistochemistry in McLeod myopathy. Muscle Nerve 2001;24:1346-51.
11. Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1979;42:575-83.
12. Jung HH, Hergersberg M, Vogt M, et al. McLeod phenotype associated with a XK missense mutation without hematologic, neuromuscular, or cerebral involvement. Transfusion 2003;43:928-38.
13. Russo DC, Lee S, Reid ME, et al. Point mutations causing the McLeod phenotype. Transfusion 2002;42:287-93.
14. Daniels GL, Weinauer F, Stone C, et al. A combination of the effects of rare genotypes at the XK and KEL blood group loci results in absence of Kell system antigens from the red blood cells. Blood 1996;88:4045-50.
15. Walker RH, Danek A, Jung HH, et al. McLeod syndrome presenting with hepatic disease. Mov Disord 2005;20:S6-S7.
16. Danek A, Uttner I, Vogl T, et al. Cerebral involvement in McLeod syndrome. Neurology 1994;44:117-20.
17. Barr AN, Heinze WJ, Dobben GD, et al. Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy. Neurology 1978;28:1196-200.
18. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001;50:755-64.
19. Danek A, Tison F, Rubio J, et al. The chorea of McLeod syndrome. Mov Disord 2001;16:882-9.
20. Kawakami T, Takiyama Y, Sakoe K, et al. A case of McLeod syndrome with unusually severe myopathy. J Neurol Sci 1999;166:36-9.
21. Ueyama H, Kumamoto T, Nagao S, et al. A novelmutation of the McLeod syndrome gene in a Japanese family. J Neurol Sci 2000;176:151-4.
22. Singleton BK, Green CA, Renaud S, et al. McLeod syndrome resulting from a novel XK mutation. Br J Haematol 2003;122:682-5.
23. Wendel S, Fontao-Wendel R, Levi JE, et al. A McLeod phenotype detected by random screening for K: -4 [Kp(b-)] blood donors in Brazil. Transfusion 2004;44:1579-87.
24. Francke U, Ochs HD, de Martinville B, et al. Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. Am J Hum Genet 1985;37:250-67.
25. Bertelson CJ, Pogo AO, Chaudhuri A, et al. Localization of the McLeod locus (XK) within Xp21 by deletion analysis. Am J Hum Genet 1988;42:703-11.
26. Frey D, Machler M, Seger R, et al. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood 1988;71:252-5.
27. de Saint Basile G, Bohler MC, Fischer A, et al. Xp21 DNA microdeletion in a patient with chronic granulomatous disease, retinitis pigmentosa, and McLeod phenotype. Hum Genet 1988;80:85-9.
28. El Nemer W, Colin Y, Collec E, et al. Analysis of deletions in three McLeod patients: exclusion of the XS locus from the Xp21.1-Xp21.2 region. Eur J Immunogenet 2000;27:29-33.
29. Ho MF, Chalmers RM, Davis MB, et al. A novel point mutation in the MacLeod syndrome gene in neuroacanthocytosis. Ann Neurol 1996;39:672-5.
30. Hanaoka N, Yoshida K, Nakamura A, et al. A novel frameshift mutation in the McLeod syndrome gene in a Japanese family. J Neurol Sci 1999;165:6-9.
31. Supple SG, Iland HJ, Barnett MH, et al. A spontaneous novel XK gene mutation in a patient with McLeod syndrome. Br J Haematol 2001;115:369-72.
32. Dotti MT, Battisti C, Malandrini A, et al. McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. Mov Disord 2000;15:1282-4.
33. Zeman A, Daniels G, Tilley L, et al. McLeod syndrome: life-long neuropsychiatric disorder due to a novel mutation of the XK gene. Psychiatr Genet 2005;15:291-3.
34. Starling A, Schlesinger D, Kok F, et al. A family with McLeod syndrome and calpainopathy with clinically overlapping diseases. Neurology 2005;65:1832-3.
35. Rutledge T, Cosson P, Manolios N, et al. Transmembrane helical interactions: zeta-chain dimerization and functional association with the T-cell antigen receptor. EMBO J 1992;11:3245-54.
36. Calenda G, Peng JB, Redman CM, et al. Identification of two new members, XPLAC and XTES, of the XK family. Gene 2006;370:6-16.
37. Lee S, Russo DC, Reiner AP, et al. Molecular defects underlying the Kell null phenotype. J Biol Chem 2001;276:27281-9.
38. Yazdanbakhsh K, Lee S, Yu Q, et al. Identification of a defect in the intracellular trafficking of a Kell blood group variant. Blood 1999;94:310-8.
39. Redman CM, Marsh WL, Scarborough A, et al. Biochemical studies on McLeod phenotype red cells and isolation of Kx antigen. Br J Haematol 1988;68:131-6.
40. Burset M, Seledtsov IA, Solovyev VV. Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res 2000;28:4364-75.
41. Thanaraj TA, Clark F. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res 2001;29:2581-93.
42. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis: a clinical, haematological and pathological study of 19 cases. Brain 1991;114:13-49.
43. Redman CM, Lee S. An overview of the Kell blood group system and endothelins. Mov Disord 2005;20:1676.
44. van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol 2000;60:385-405.
45. Faillace RT, Kingston WJ, Nanda NC, et al. Cardiomyopathy associated with the syndrome of amyotrophic chorea and acanthocytosis. Ann Intern Med 1982;96:616-7.
46. Takashima H, Sakai T, Iwashita H, et al. A family of McLeod syndrome, masquerading as choreaacanthocytosis. J Neurol Sci 1994;124:56-60.
47. Malandrini A, Fabrizi GM, Truschi F, et al. Atypical McLeod syndrome manifested as X-linked chorea-acanthocytosis, neuromyopathy and dilated cardiomyopathy: report of a family. J Neurol Sci 1994;124:89-94.
48. Holland SM. Chronic granulomatous disease and MLS. Mov Disord 2005;20:1677.
49. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
50. Marsh WL, Schnipper EF, Johnson CL, et al. An individual with McLeod syndrome and the Kell blood group antigen K (K1). Transfusion 1983;23:336-8.
51. Oechsner M, Buchert R, Beyer W, et al. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurgery Psychiatry 2001;70:517-20.
52. Wimer BM, Marsh WL, Taswell HF, et al. Haematological changes associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1977;36:219-24.
53. Carter ND, Morgan JE, Monaco AP, et al. Dystrophin expression and genotypic analysis of two cases of benign X linked myopathy (McLeod's syndrome). J Med Genet 1990;27:345-7.
54. Peng J, Redman C, Wu X, et al. Insights into huge deletions around the XK locus that are associated with McLeod phenotypes and characterization of two novel cases Gene (in press).
55. Walker RH, Jung HH, Tison F, et al. Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome. Movement Disorders 2006;DOI 10.1002/mds.21224.
56. Wada M, Kimura M, Daimon M, et al. An unusual phenotype of McLeod syndrome with late onset axonal neuropathy. J Neurol Neurosurg Psych 2003;74:1697-8.
57. Klempir J, Zarubova K, Pisacka M, et al. McLeod syndrome: A case report. Eur J Neurol 2006;13 Suppl. 2:90.